Abstract: The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of genetic engineering. The diabody-type bispecific antibody shows a more remarkable effect than the conventional diabody-type bispecific antibodies and chemically synthesized bispecific antibodies even in a very low concentration and in the absence of the super antigen.
Abstract: There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an iso lated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 with an affinity binding constant of at least 108 M?1, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO. 2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier. Also disclosed are prognostic and diagnostic assays.
Type:
Grant
Filed:
February 16, 2000
Date of Patent:
December 1, 2009
Assignee:
Oregon Health & Science University
Inventors:
Gail M. Clinton, Adam Evans, William D. Henner
Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs.
Abstract: An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8-fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interferred with EGF activation of the EGF receptor in cotransfected cells as demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression.
Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.
Type:
Grant
Filed:
August 5, 2003
Date of Patent:
October 20, 2009
Assignees:
The Johns Hopkins University, Vermillion, Inc.
Inventors:
Daniel W. Chan, Zhen Zhang, Eric Fung, Xiao-Ying Meng
Abstract: The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity selected population, was chemically synthesized and characterized for its binding activities to the recombinant extracellular domain of ErbB-2. The synthetic peptide exhibits high specificity to ErbB-2 as well as to ErbB-1, another member of ErbB family. Thus, this peptide can be employed in cancer imaging or therapeutic agent targeting to malignant cells ErbB-2 receptor.
Type:
Grant
Filed:
July 3, 2003
Date of Patent:
September 8, 2009
Assignee:
The Curators of The University of Missouri
Abstract: Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described. In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
Type:
Grant
Filed:
May 5, 2006
Date of Patent:
August 18, 2009
Assignee:
Micromet AG
Inventors:
Bernd Dorken, Gert Riethmuller, Peter Kufer, Ralf Lutterbuse, Ralf Bargou, Anja Loffler
Abstract: The present invention relates to a series of new chemical agents that demonstrate anti-tumor activity. More particularly, the present invention relates to molecules, referred to as “combi-molecules”, that combine two major mechanisms of anti-tumor action. A combi-molecule is capable of degrading to a ligand involved in cell signaling pathways and to an agent capable of damaging DNA. More specifically, the present invention relates to molecules capable of blocking epidermal growth factor receptor (EGFR) mediated signal transduction and capable of damaging DNA. The present invention also relates to a general method of synthesis of these combi-molecules.
Type:
Grant
Filed:
February 26, 2002
Date of Patent:
August 11, 2009
Assignee:
McGill University
Inventors:
Bertrand J. Jean-Claude, Fabienne Dudouit, Stephanie Matheson
Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein ASC in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of breast cancer.
Type:
Grant
Filed:
April 14, 2006
Date of Patent:
July 28, 2009
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Gabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
Type:
Grant
Filed:
May 5, 2006
Date of Patent:
May 26, 2009
Assignee:
Genentech, Inc.
Inventors:
Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
Abstract: An antitumor agent, which is a combination of an oxidoreductase, such as xanthine oxidase chemically conjugated to a polymer such as poly ethylene glycol, for initial administration and accumulation in the tumor tissue followed by administration and of a substrate for the oxidoreductase which releases reactive oxygen species. Improved tumor selective cytotoxic activity results.
Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and anti-hormonal compounds, such as anti-estrogens.
Type:
Grant
Filed:
September 9, 2005
Date of Patent:
March 3, 2009
Assignee:
Genetech, Inc.
Inventors:
Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
Abstract: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.
Type:
Grant
Filed:
October 17, 2005
Date of Patent:
February 24, 2009
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Béatrice Guagler, Benoit Van den Eynde, Pierre van den Bruggen, Thierry Boon-Falleur
Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents.
Type:
Grant
Filed:
May 5, 2006
Date of Patent:
February 3, 2009
Assignee:
Genentech, Inc.
Inventors:
Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
Abstract: Provided herein is disclosure about the identification and characterization of disease and cancer associated antigen PIPA. The invention also provides a family of monoclonal antibodies that bind to antigen PIPA, and methods of diagnosing and treating various human cancers and diseases that express PIPA.
Type:
Grant
Filed:
November 13, 2003
Date of Patent:
July 29, 2008
Assignee:
Raven biotechnologies, inc.
Inventors:
Jennie P. Mather, Ronghao Li, Tony W. Liang
Abstract: An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8 fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interfered with EGF activation of the EGF receptor in cotransfected cells demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression.
Abstract: DNAs are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.